PCORI awards $55M in new projects

The Patient-Centered Outcomes Research Institute (PCORI) has approved $54.8 million in funding to support 33 new patient-centered comparative clinical effectiveness research projects focusing on conditions including cardiovascular disease, diabetes, chronic pain and cancer.

The studies will compare different approaches to delivering care and improving patients’ access to care, and several projects will focus on specific patient populations such as racial and ethnic minorities and low-income individuals.

The approved studies are based at institutions and organizations in 18 states and were selected from 325 applications. With this latest round of awards, PCORI has approved nearly $549 million in support of a total of 313 research projects and initiatives since it began funding research in 2012. PCORI expects to award roughly $1 billion in research support over the two-year period from 2014 through 2015.

Details about the newly approved studies are available at www.pcori.org/pfaawards.

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.